Head-to-head · free
GSAT vs Pfizer
GSAT vs PFE — return on capital, cash generation, margins and balance sheet side by side.
GSAT
2 / 7
measures where GSAT leads
PFE
5 / 7
measures where PFE leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | GSAT · FY2025 | PFE · FY2025 |
|---|---|---|
| Revenue | $273.0M | $62.6B |
| Net income | (8.7M) | $7.8B |
| Revenue growth (yearly, multi-year) | 21.7% | -6.3% |
| Free cash flow | — | $9.1B |
| Free cash flow margin | — | 14.5% |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -5.4% | 8.9% |
| Gross margin | 64.8% | 74.3% |
| Operating margin | 5.4% | 27.8% |
| Net debt / EBITDA | 0.38x | 4.23x |
Figures are as reported by each company; latest fiscal year shown.
Where GSAT's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Pfizer's cash went (FY2025)
- Capital spending
- $2.6B
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free